Resistance to Targeted Therapies in Breast Cancer

Resistance to Targeted Therapies in Breast Cancer

Prosperi, Jenifer R.

Springer International Publishing AG

12/2017

184

Dura

Inglês

9783319701417

15 a 20 dias


Versão ebook 139,99 €

We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling).
1.Invasive Breast Cancer Therapy 2017: How Well Are We Hitting The Target? 2.Resistance to HER2-targeted therapy 3.Endocrine Resistance and Breast Cancer Stem Cells - The Inflammatory Connection That Could Lead to New and Improved Therapy Outcomes 4.EGFR Resistance 5.Targeting FGFR for the treatment of breast cancer 6.Targeted Therapies in Breast Cancer 7.Future paradigm of breast cancer resistance and treatment
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.